InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The firm issued a sell rating on the stock.

InspireMD Trading Down 4.1 %

NYSE:NSPR opened at $2.12 on Tuesday. InspireMD has a 1 year low of $0.96 and a 1 year high of $3.85. The firm’s fifty day simple moving average is $2.46 and its 200 day simple moving average is $2.73. The firm has a market capitalization of $49.73 million, a PE ratio of -1.96 and a beta of 0.83.

InspireMD (NYSE:NSPR) last posted its earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The business had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.65 million. During the same period last year, the business posted ($0.60) EPS. As a group, analysts anticipate that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Trading of InspireMD

Several hedge funds and other institutional investors have recently bought and sold shares of NSPR. Marshall Wace LLP acquired a new stake in InspireMD in the 2nd quarter worth $4,670,000. Nantahala Capital Management LLC grew its position in InspireMD by 16.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock worth $5,807,000 after purchasing an additional 298,406 shares during the last quarter. Northern Trust Corp acquired a new stake in InspireMD in the 4th quarter worth $80,000. Avestar Capital LLC acquired a new stake in InspireMD in the 3rd quarter worth $65,000. Finally, Renaissance Technologies LLC acquired a new stake in InspireMD in the 2nd quarter worth $36,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.